Anidulafungin compared with fluconazole in severely ill patients with candidemia and other forms of invasive candidiasis: Support for the 2009 IDSA treatment guidelines for candidiasis

Critical Care

Volumn 15, Issue 5, 2011, Pages

  Kett, Daniel H ^a   Shorr, Andrew F ^b   Reboli, Annette C ^c   Reisman, Arlene L ^d   Biswas, Pinaki ^d   Schlamm, Haran T ^d  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b WASHINGTON HOSPITAL CENTER   (United States)

^c Ferry Terminal Building ^*  (United States)

^d PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIDULAFUNGIN; FLUCONAZOLE; ANTIFUNGAL AGENT; ECHINOCANDIN;

ADULT; APACHE; ARTICLE; CANDIDEMIA; CRITICAL ILLNESS; DRUG EFFICACY; FEMALE; HUMAN; INVASIVE CANDIDIASIS; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; NONHUMAN; POST HOC ANALYSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; SECONDARY ANALYSIS; AGED; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; HOSPITALIZATION; MIDDLE AGED; MORTALITY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; UNITED STATES;

AGED; ANTIFUNGAL AGENTS; CANDIDEMIA; CANDIDIASIS, INVASIVE; DOUBLE-BLIND METHOD; ECHINOCANDINS; FEMALE; FLUCONAZOLE; HUMANS; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SOCIETIES, MEDICAL; TREATMENT OUTCOME; UNITED STATES;

EID: 80054866137     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc10514     Document Type: Article

References (30)

1. Eggimann P, Garbino J, Pittet D. Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis 2003, 3:685-702. 10.1016/S1473-3099(03)00801-6, 14592598.
2. Horn DL, Fishman JA, Steinbach WJ, Anaissie EJ, Marr KA, Olyaei AJ, Pfaller MA, Weiss MA, Webster KM, Neofytos D. Presentation of the PATH Alliance registry for prospective data collection and analysis of the epidemiology, therapy, and outcomes of invasive fungal infections. Diagn Microbiol Infect Dis 2007, 59:407-414. 10.1016/j.diagmicrobio.2007.06.008, 17888614.
3. Kullberg BJ, Oude Lashof AM. Epidemiology of opportunistic invasive mycoses. Eur J Med Res 2002, 7:183-191.
4. Lipsett PA. Surgical critical care: fungal infections in surgical patients. Crit Care Med 2006, 34:S215-S224. 10.1097/01.CCM.0000231883.93001.E0, 16917426.
5. Richardson MD. Changing patterns and trends in systemic fungal infections. J Antimicrob Chemother 2005, 56(Suppl 1):i5-i11.
6. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004, 39:309-317. 10.1086/421946, 15306996.
7. Blumberg HM, Jarvis WR, Soucie JM, Edwards JE, Patterson JE, Pfaller MA, Rangel-Frausto MS, Rinaldi MG, Saiman L, Wiblin RT, Wenzel RP. Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study; The National Epidemiology of Mycosis Survey. Clin Infect Dis 2001, 33:177-186. 10.1086/321811, 11418877.
8. Kett DH, Azoulay E, Echeverria PM, Vincent JL. Candida bloodstream infections in intensive care units: analysis of the extended prevalence of infection in intensive care unit study. Crit Care Med 2011, 39:665-670. 10.1097/CCM.0b013e318206c1ca, 21169817.
9. Garbino J, Kolarova L, Rohner P, Lew D, Pichna P, Pittet D. Secular trends of candidemia over 12 years in adult patients at a tertiary care hospital. Medicine (Baltimore) 2002, 81:425-433.
10. Leroy O, Gangneux JP, Montravers P, Mira JP, Gouin F, Sollet JP, Carlet J, Reynes J, Rosenheim M, Regnier B, Lortholary O. Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006). Crit Care Med 2009, 37:1612-1618. 10.1097/CCM.0b013e31819efac0, 19325476.
11. Pappas PG, Rex JH, Lee J, Hamill RJ, Larsen RA, Powderly W, Kauffman CA, Hyslop N, Mangino JE, Chapman S, Horowitz HW, Edwards JE, Dismukes WE. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 2003, 37:634-643. 10.1086/376906, 12942393.
12. Tortorano AM, Peman J, Bernhardt H, Klingspor L, Kibbler CC, Faure O, Biraghi E, Canton E, Zimmermann K, Seaton S, Grillot R. Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur J Clin Microbiol Infect Dis 2004, 23:317-322. 10.1007/s10096-004-1103-y, 15029512.
13. Apisarnthanarak A, Naknarongkij N, Kiratisin P, Mundy LM. Risk factors and outcomes of Candida albicans and non-albicans Candida species at a Thai tertiary care center. Am J Infect Control 2009, 37:781-782. 10.1016/j.ajic.2009.04.289, 19874981.
14. Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Ellis D, Tullio V, Rodloff A, Fu W, Ling TA. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion. J Clin Microbiol 2010, 48:1366-1377. 10.1128/JCM.02117-09, 2849609, 20164282.
15. Yang CW, Barkham TM, Chan FY, Wang Y. Prevalence of Candida species, including Candida dubliniensis, in Singapore. J Clin Microbiol 2003, 41:472-474. 10.1128/JCM.41.1.472-474.2003, 149596, 12517898.
16. Yap HY, Kwok KM, Gomersall CD, Fung SC, Lam TC, Leung PN, Hui M, Joynt GM. Epidemiology and outcome of Candida bloodstream infection in an intensive care unit in Hong Kong. Hong Kong Med J 2009, 15:255-261.
17. Charlier C, Hart E, Lefort A, Ribaud P, Dromer F, Denning DW, Lortholary O. Fluconazole for the management of invasive candidiasis: where do we stand after 15 years?. J Antimicrob Chemother 2006, 57:384-410. 10.1093/jac/dki473, 16449304.
18. Pappas PG, Kauffman CA, Andes D, Benjamin DK, Calandra TF, Edwards JE, Filler SG, Fisher JF, Kullberg BJ, Ostrosky-Zeichner L, Reboli AC, Rex JH, Walsh TJ, Sobel JD. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009, 48:503-535. 10.1086/596757, 19191635.
19. Pfaller M, Boyken I, Hollis RJ, Kroeger J, Messer SA, Tendolkar S, Diekema DJ. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol 2008, 46:150-156. 10.1128/JCM.01901-07, 2224271, 18032613.
20. Mora-Duarte J, Betts R, Rotstein C, Colombo AL, Thompson-Moya L, Smietana J, Lupinacci R, Sable C, Kartsonis N, Perfect J. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002, 347:2020-2029. 10.1056/NEJMoa021585, 12490683.
21. Kuse ER, Chetchotisakd P, da Cunha CA, Ruhnke M, Barrios C, Raghunadharao D, Sekhon JS, Freire A, Ramasubramanian V, Demeyer I, Nucci M, Leelarasamee A, Jacobs F, Decruyenaere J, Pittet D, Ullmann AJ, Ostrosky-Zeichner L, Lortholary O, Koblinger S, Diekmann-Berndt H, Cornely OA. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 2007, 369:1519-1527. 10.1016/S0140-6736(07)60605-9, 17482982.
22. Pappas PG, Rotstein CM, Betts RF, Nucci M, Talwar D, De Waele JJ, Vazquez JA, Dupont BF, Horn DL, Ostrosky-Zeichner L, Reboli AC, Suh B, Digumarti R, Wu C, Kovanda LL, Arnold LJ, Buell DN. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007, 45:883-893. 10.1086/520980, 17806055.
23. Reboli AC, Rotstein C, Pappas PG, Chapman SW, Kett DH, Kumar D, Betts R, Wible M, Goldstein BP, Schranz J, Krause DS, Walsh TJ. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007, 356:2472-2482. 10.1056/NEJMoa066906, 17568028.
24. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985, 13:818-829. 10.1097/00003246-198510000-00009, 3928249.
25. American College of Chest Physicians/Society of Critical Care Medicine American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992, 20:864-874. 10.1097/00003246-199206000-00025, 1597042, American College of Chest Physicians/Society of Critical Care Medicine.
26. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976, 16:31-41. 10.1159/000180580, 1244564.
27. Guery BP, Arendrup MC, Auzinger G, Azoulay E, Borges SM, Johnson EM, Muller E, Putensen C, Rotstein C, Sganga G, Venditti M, Zaragoza CR, Kullberg BJ. Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients, Part II: Treatment. Intensive Care Med 2009, 35:206-214. 10.1007/s00134-008-1339-6, 18972100.
28. DiNubile MJ, Lupinacci RJ, Strohmaier KM, Sable CA, Kartsonis NA. Invasive candidiasis treated in the intensive care unit: observations from a randomized clinical trial. J Crit Care 2007, 22:237-244. 10.1016/j.jcrc.2006.11.004, 17869975.
29. Dupont BF, Lortholary O, Ostrosky-Zeichner L, Stucker F, Yeldandi V. Treatment of candidemia and invasive candidiasis in the intensive care unit: post hoc analysis of a randomized, controlled trial comparing micafungin and liposomal amphotericin B. Crit Care 2009, 13:R159. 10.1186/cc8117, 2784386, 19804626.
30. Ferrada MA, Kett DH, Quartin AA, Morris MI. Epidemiology, treatment and outcomes of candidemia in mechanically ventilated patients [abstract]. Proceedings of the 48th Annual ICAAC/IDSA 46th Annual Meeting, Washington, DC, October 25-28 2008, 631.